Saskatchewan residents with cystic fibrosis now have another publicly funded treatment option. Effective Aug. 1, the provincial drug plan will cover Alyftrek for eligible patients aged six and older who meet established medical criteria.
What the coverage means
The medication, approved for people who carry one of 266 rare genetic mutations that cause cystic fibrosis, joins other modulators already funded in the province. Health officials say the addition increases the share of patients eligible for modulator therapy to more than 95 per cent in Saskatchewan.
“Our government is pleased to cover the cost of this new treatment for Saskatchewan patients with cystic fibrosis,” Health Minister Jeremy Cockrill said in a news release. “Alyftrek has been shown to improve quality of life in patients with CF, so expanding coverage puts CF patients first by helping them to lead healthier lives.”
While Alyftrek is not a cure, it is designed to control symptoms and slow disease progression by targeting the underlying genetic cause in eligible patients. The provincial decision follows a recommendation issued in July 2025 and price negotiations through the pan-Canadian Pharmaceutical Alliance completed in July 2026.
How many people are affected
According to the Canadian Cystic Fibrosis Registry, more than 4,500 people in Canada live with cystic fibrosis, including nearly 150 in Saskatchewan. The province already covers other modulators such as Trikafta, Orkambi and Kalydeco, and Alyftrek expands options for people with mutations not addressed by those treatments.
- Coverage start date: Aug. 1
- Affected age group: six years and older
- Mutations covered: 266 rare CF-causing mutations
- Estimated provincial CF population: ~150
Practical guidance for patients and families
Health officials encourage patients with cystic fibrosis — and parents or guardians of children who have the disease — to speak with their physician if they think Alyftrek could be appropriate. Coverage is for those who meet medical eligibility criteria, so prescription and clinical review are required before public funding is applied.
For families, the coverage decision removes a major barrier to access. Modulator drugs are expensive, and public funding can determine whether a patient receives a treatment that may improve lung function, reduce infections and slow disease progression.
Provincial and pan-Canadian processes
The route to coverage combined a clinical assessment and provincial funding decision with pan-Canadian price negotiations. The provincial announcement cited the recommendation from 2025 and confirmed the completion of price talks in July 2026 — a process that has become routine for expensive, specialised medicines across Canada.
| Drug | Already covered? |
|---|---|
| Trikafta | Yes |
| Orkambi | Yes |
| Kalydeco | Yes |
| Alyftrek | Now covered (as of Aug. 1) |
Broader context
Cystic fibrosis is an inherited condition that primarily affects the lungs and digestive system. Treatments that modify the function of the defective protein produced by the CFTR gene have reshaped care in recent years, turning what was once a relentlessly progressive illness into a condition where many patients live longer and have a better quality of life.
That evolution has also raised questions about equitable access across Canada, pricing negotiations and the limits of public drug plans. Saskatchewan’s decision reflects one province’s choice to expand access after national-level recommendations and negotiated pricing agreements.
Patients interested in Alyftrek should contact their treating clinician or the provincial drug plan for details about eligibility, coverage terms and how to apply. Clinical assessment remains the key step to determine whether the medication is appropriate for an individual patient.
This report will be updated if the provincial health ministry provides further implementation details or guidance for clinicians and pharmacies.
